Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 17/20 | 0.44 |
| ▸ | DPP8 | Q6V1X1 | 7/20 | 0.43 |
| ▸ | DPP9 | Q86TI2 | 7/20 | 0.43 |
| ▸ | DPP7 | Q9UHL4 | 5/20 | 0.43 |
| ▸ | FAP | Q12884 | 2/20 | 0.43 |
| ▸ | CES2 | O00748 | 1/20 | 0.40 |
| ▸ | CES1 | P23141 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1024006 | 0.81 | DPP4 (0.47) | DPP4DPP8DPP9DPP7FAP | |
| Hydrochloric Acid SCHEMBL389541 | 0.80 | DPP4 (0.46) | DPP4DPP8DPP9DPP7FAP | |
| SCHEMBL13967791 | 0.73 | CES2 (0.46) | CES2CES1 | |
| SCHEMBL13967805 | 0.72 | CES2 (0.50) | CES2CES1 | |
| SCHEMBL13967804 | 0.72 | CES2 (0.50) | CES2CES1 | |
| Isoleucine SCHEMBL28238226 | 0.70 | DPP4 (0.49) | DPP4DPP8DPP9DPP7FAP | |
| SCHEMBL13086679 | 0.70 | EPHX1 (0.46) | DPP4DPP8DPP9DPP7FAP | |
| SCHEMBL1952567 | 0.70 | EPHX1 (0.50) | DPP4DPP8DPP9DPP7FAP | |
| SCHEMBL28915740 | 0.70 | DPP4 (0.46) | DPP4DPP8DPP9DPP7FAP | |
| SCHEMBL16204545 | 0.70 | DPP4 (0.50) | DPP4DPP8DPP9DPP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7368421-B2 | Use of dipeptidyl peptidase IV inhibitors in the treatment of multiple sclerosis | PROBIODRUG AG (DE) | 2008-05-06 | — | — | US | disclosed |
| EP-1399471-B1 | USE OF DIPEPTIDYL PEPTIDASE IV INHIBITORS AS THERAPEUTICS FOR NEUROLOGICAL DISORDERS | PROBIODRUG AG (DE) | 2008-01-30 | — | — | EP | disclosed |